Opthea
Follow
Get notifications in MyBN when activity occurs.
Industry Lists
Public Companies - non WAOpthea Limited (OPT) is a biotechnology company focused on development of new drugs for the treatment of eye diseases.
Opthea's lead asset, OPT - 302, is a soluble form of VEGFR-3 in clinical development as a novel therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Wet AMD and DME are causes of blindness in the elderly and diabetic populations respectively, and are increasing in prevalence worldwide.
Contact Details
Level 4, 650 Chapel Street, SOUTH YARRA VIC 3141
03 9826 0399
Lists and Charts
Share price
Closing price for the last 90 trading days
Powered by Morningstar ®
Total Shareholder Return as at 30/09/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 77th | Opthea | 155% | -23% |
1743 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Opthea | $980k |
1333 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Company Activity
| NEW ROLE: Peter Lang, | 04 Oct 2024 |
| NEW ROLE: Anshul Thakral, Non-Executive Director | 07 Aug 2024 |
| NEW ROLE: Sujal Shah, Non-Executive Director | 07 Aug 2024 |
| ECM DEAL: New deal has been added | 22 Jul 2024 |
| NEW ROLE: Timothy Morris, | 30 Oct 2023 |
| NEW ROLE: Joel Naor, | 23 Sep 2022 |
| NEW ROLE: Susan Orr, Non-Executive Director | 26 May 2022 |
| NEW ROLE: Quinton Oswald, Non-Executive Director | 26 May 2022 |
| NEW ROLE: Karen Adams, Company Secretary, Vice President of Finance | 13 Apr 2022 |
